Year: 2019

It’s no secret that health care costs continue to rise, and new research from the Commonwealth Fund (TCF) indicates that Americans are paying more for their premiums and deductibles than ever before. …read more […]

One exec called the alliance “a complete game-changer for the industry.” …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on Nov. 22. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on Nov. 22. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. …read more […]

The company is holding on to a record amount of liquid assets, which serves as a warning for investors Continue reading… …read more […]

Is Genesis Energy, L.P. (NYSE:GEL) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […] …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. The deal is expected to help to broaden the Swiss drugmaker’s range of heart medicines and shore up growth threatened by patent expirations. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on November 22, Novartis said in a statement, adding the transaction had been approved by the boards of directors of both …read more […]

Company beats on earnings, misses revenue forecasts Continue reading… …read more […]

Q3 2019 Uniti Group Inc Earnings Call …read more […]

Private equity firm Silver Lake is nearing a deal to acquire First Advantage that could value the background checks provider at more than $1.5 billion, including debt, people familiar with the matter said on Sunday. Silver Lake declined to comment. First Advantage and its owner, Symphony Technology Group (STG), did not respond to requests for comment. …read more […]

Some hedge funders out there appear to have made a strong bet shorting the bitcoin market over the past week, data from the Commodities Futures Trading Commission shows. The post Hedge funds were short bitcoin going into this downturn, CFTC report show appeared first on The Block. …read more […]

Black borrowers are on average borrowing more and defaulting at higher rates, according to New York Fed data. …read more […]